US FTC backs patent office move to promote competition

19 June 2024
usa_flag_big

In the USA, the Federal Trade Commission (FTC) has  expressed support for a proposed rule to require the disclosure of all pre-institution patent settlement agreements.

Proposed by the US Patent and Trademark Office (USPTO),  the change aims to enhance the monitoring and prevention of anticompetitive practices.

If enacted, the new rules would mandate parties to submit all patent settlement agreements, including collateral agreements, before the PTAB decides whether to institute a trial.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical